Introduction And Importance: While the treatment approach for sarcomas seems straightforward and well-defined, we often encounter several diagnostic or therapeutic challenges in clinical practice. This article presents a case of retroperitoneal leiomyosarcoma in a patient with chronic kidney disease, highlighting the complexity of managing such cases.
Case Report: A 63-year-old woman with a history of chronic kidney disease presented with a progressively enlarging mass in her right flank. A CT scan revealed a retroperitoneal mass affecting the muscular layer of the right lumbar ureter, without invading the kidney. Percutaneous biopsies concluded to a smooth muscle tumor with positive anti-caldesmone and anti-desmin antibodies. A 99 m Tc DMSA renal revealed significant impairment of the right kidney function while the left kidney function remained normal. The surgical procedure involved removing the mass, as well as the right kidney and ureter. Histopathological examination confirmed the diagnosis of leiomyosarcoma. No locoregional recurrence or metastases were noted after a 13-month follow-up.
Discussion: Leiomyosarcomas are malignant tumors that can affect various organs, with retroperitoneum being the second most common location. A CT scan and abdominal MRI are standard imaging technique to evaluate this disease. Percutaneous biopsy and pathology are performed to confirm the nature of the tumor, especially when neoadjuvant treatment is necessary for metastatic tumors. Compartmental resection with clear margins is the only potential curative treatment. Even after R0 resection the risk of recurrence varies between 20 and 75 %.
Conclusion: Managing retroperitoneal leiomyosarcoma, especially in patients with comorbidities like chronic kidney disease, necessitates a multidisciplinary approach.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ijscr.2024.110581 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Association of trimethylamine N-oxide and metabolites with kidney function decline in patients with chronic kidney disease.
Clin Nutr
December 2024
Division of Nephrology, Department of Medicine, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, and School of Medicine, Tzu Chi University, Hualien, Taiwan. Electronic address:
Background: Trimethylamine N-oxide (TMAO) is a gut microbial metabolite derived from dietary l-carnitine and choline. High plasma TMAO levels are associated with cardiovascular disease and overall mortality, but little is known about the associations of TMAO and related metabolites with the risk of kidney function decline among patients with chronic kidney disease (CKD).
Methods: We prospectively followed 152 nondialysis patients with CKD stages 3-5 and measured plasma TMAO and related metabolites (trimethylamine [TMA], choline, carnitine, and γ-butyrobetaine) via liquid chromatography‒mass spectrometry.
Impact on fluid balance of an optimized restrictive strategy targeting non-resuscitative fluids in intensive care patients with septic shock: a single-blind, multicenter, randomized, controlled, pilot study.
Crit Care
December 2024
Division of Anesthesia, Critical Care, Pain and Emergency Medicine, UR‑UM103 IMAGINE, University of Montpellier, Nimes University Hospital, Nîmes, France.
Background: In septic shock, the classic fluid resuscitation strategy can lead to a potentially harmful positive fluid balance. This multicenter, randomized, single-blind, parallel, controlled pilot study assessed the effectiveness of a restrictive fluid strategy aiming to limit daily volume.
Methods: Patients 18-85 years' old admitted to the ICU department of three French hospitals were eligible for inclusion if they had septic shock and were in the first 24 h of vasopressor infusion.
Efficacy and Safety of Sodium Zirconium Cyclosilicate in the Management of Hyperkalemia in Patients with Heart Failure with Reduced and Mildly Reduced Ejection Fraction and Chronic Kidney Disease Treated with Spironolactone: rational for and design of the REGISTA-K trial.
J Card Fail
December 2024
Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan. Electronic address:
Background: To evaluate whether sodium zirconium cyclosilicate (SZC) enables the uptitration of spironolactone without increasing the risk of hyper- and hypokalemia in patients with heart failure with reduced and mildly reduced ejection fraction (HFrEF and HFmrEF) and moderate/severe chronic kidney disease (CKD) who developed hyperkalemia during treatment with suboptimal spironolactone dose.
Methods: The REGISTA-K is a randomized, double-blind, placebo-controlled, multicenter trial that examined the efficacy and safety of SZC in uptitrating spironolactone without the occurrence of hyperkalemia or hypokalemia. A total of 266 patients with HFrEF and HFmrEF and hyperkalemia will be randomized in a 1:1 ratio to receive either SZC or placebo after treating hyperkalemia with SZC at 25 sites in Japan.
International prevalence patterns of low eGFR in adults aged 18-60 without traditional risk factors from a population-based cross-sectional disadvantaged populations eGFR epidemiology (DEGREE) study.
Kidney Int
December 2024
Department of Medical Statistics, London School of Hygiene & Tropical Medicine, London, UK.
The disadvantaged populations eGFR (estimated glomerular filtration rate) epidemiology (DEGREE) study was designed to gain insight into the burden of chronic kidney disease (CKD) of undetermined cause (CKDu) using standard protocols to estimate the general-population prevalence of low eGFR internationally. Therefore, we estimated the age-standardized prevalence of eGFR under 60 ml/min per 1.73m in adults aged 18-60, excluding participants with commonly known causes of CKD; an ACR (albumin/creatinine ratio) over 300 mg/g or equivalent, or self-reported or measured (HT) hypertension or (DM) diabetes mellitus, stratified by sex and location.
View Article and Find Full Text PDFUse of vancomycin and acute kidney injury in critically ill patients with sepsis or septic shock: A retrospective observational cohort study.
Rev Esp Anestesiol Reanim (Engl Ed)
December 2024
Departamento de Farmacia, Clínica Universidad de Navarra, Pamplona, Universidad de Navarra, Spain.
Introduction: The independent association of vancomycin with Acute Kidney Injury (AKI) in the critically ill patient with sepsis or septic Shock is controversial. The aim of this study was to evaluate the incidence of AKI in a cohort of patients with sepsis or septic Shock with an adequate and strict monitoring of vancomycin, guided by the area under the concentration-time curve in relation to the minimum inhibitory concentration (AUC/MIC ratio).
Material And Methods: Retrospective cohort study on 106 patients admitted to the ICU with a diagnosis of sepsis or septic shock with vancomycin treatment, consecutively from January 2017 to December 2019.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!